Form 4 for ARWR ARROWHEAD PHARMACEUTICALS, INC.
Accepted 2025-01-07 00:00:00 ET · period of report 2025-01-04 · accession 0001628280-25-000805 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-01-07 | 2025-01-06+ | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $19.77 | -45.2K | 465.4K | -9% | -$893.1K |
| 2025-01-07 | 2025-01-04 | ARWR | Myszkowski Kenneth Allen | CFO | A - Grant | $0.00 | +100.0K | 500.6K | +25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-06 | S | D | 17,765 | $19.68 | 482,835 | D | — | — | (F4) The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $19.18 to $20.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. (F3) Partial disposition of RSUs to satisfy tax withholding obligations. (F5) Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |
| 2 | Common | Common Stock | 2025-01-06 | S | D | 9,402 | $20.10 | 473,433 | D | — | — | (F6) The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. (F3) Partial disposition of RSUs to satisfy tax withholding obligations. (F5) Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |
| 3 | Common | Common Stock | 2025-01-04 | A | A | 100,000 | $0.00 | 500,600 | D | — | — | (F1) Represents shares underlying restricted stock units with a grant date 01/04/2025, which will vest in four equal annual installments. |
| 4 | Common | Common Stock | 2025-01-07 | S | D | 10,000 | $19.69 | 455,433 | D | — | — | (F8) The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $19.62 to $19.78, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. (F5) Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |
| 5 | Common | Common Stock | 2025-01-07 | S | D | 8,000 | $19.70 | 465,433 | D | — | — | (F7) The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 19.64 to $ 19.79, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. (F3) Partial disposition of RSUs to satisfy tax withholding obligations. (F5) Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |